PhotoPoint Photodynamic Therapy Promotes Stabilization of Atherosclerotic Plaques and Inhibits Plaque Progression

Journal of the American College of Cardiology

Volumn 52, Issue 12, 2008, Pages 1024-1032

  Waksman, Ron ^a   McEwan, Pauline E ^b   Moore, Travis I ^b   Pakala, Rajbabu ^a   Kolodgie, Frank D ^c   Hellinga, David G ^a   Seabron, Rufus C ^a   Rychnovsky, Steven J ^b   Vasek, Jeffrey ^b   Scott, Robert W ^b   Virmani, Renu ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Miravant Medical Technologies   (United States)

^c CVPATH INSTITUTE   (United States)

Author keywords

atherosclerosis; macrophages; photodynamic therapy; plaque stabilization

Indexed keywords

CHOLESTEROL; MV 0611; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE STABILIZATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ILIAC ARTERY; MACROPHAGE; MALE; NONHUMAN; OPTIMAL DRUG DOSE; PHOTODYNAMIC THERAPY; PHOTOPOINT PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER; VASCULAR PATENCY;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; ILIAC ARTERY; MACROPHAGES; MALE; MESOPORPHYRINS; MYOCYTES, SMOOTH MUSCLE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; RABBITS; WOUND HEALING;

EID: 50949115875     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.06.023     Document Type: Article

References (39)

1. Farb A., Burke A.P., Tang A.L., et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 93 (1996) 1354-1363
2. Virmani R., Kolodgie F., Burke A., Farb A., and Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 (2000) 1262-1275
3. Kolodgie F., Burke A., Farb A., et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 16 (2001) 285-292
4. Hellings W.E., Peeters W., Moll F.L., and Pasterkamp G. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med 17 (2007) 162-171
5. Rioufol G., Finet G., Ginon I., et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome. Circulation 106 (2002) 804-808
6. Haft J. Multiple atherosclerotic rupture in acute coronary syndrome. Circulation 107 (2003) e65-e66
7. Burke A., Farb A., Malcom G., Liang Y.H., Smialek J., and Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336 (1997) 1276-1282
8. Davies M.J., Richardson P.D., Woolf N., Katz D.R., and Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69 (1993) 377-381
9. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
10. Gomer C., Rucker N., Ferrario A., and Wong S. Properties and applications of photodynamic therapy. Rad Res 120 (1989) 1-18
11. Henderson B., Waldow S., Mang T., Potter W.R., Malone P.B., and Dougherty T.J. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 45 (1985) 572-576
12. Prout G.J., Lin C., Benson R.J., et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med 317 (1987) 1251-1255
13. Thomas E., and Snyder W. Photodynamic therapy with tin ethylpurpurin. In: Evangelos S., Joan W.M., and Leonidas Z. (Eds). Photodynamic Therapy for Ocular Diseases (2004), Lippincott, Williams & Williams, Philadelphia, PA 231-246
14. Mansfield R., Jenkins M., Pai M., Bishop C.C., Bown S.G., and McEwan J.R. Long-term safety and efficacy of superficial femoral artery angioplasty with adjuvant photodynamic therapy to prevent restenosis. Br J Surg 89 (2002) 1538-1539
15. Rockson S.G., Lorenz D.P., Cheong W.F., and Woodburn K.W. Photoangioplasty: an emerging clinical cardiovascular role for photodynamic therapy. Circulation 102 (2000) 591-596
16. Hayase M., Woodburn K.W., Perlroth J., et al. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Cardiovasc Res 49 (2001) 449-455
17. Robinson BC, Leitch IM, Greene S, Rychnovsky S. Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy. U.S. patent 6,827,926,2004; filed May 31, 2002 and issued Dec 7, 2004.
18. Waksman R., Leitch I.M., Roessler J., et al. Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialisation in a porcine model. Heart 92 (2006) 1138-1144
19. Kockx M., De Meyer G., Buyssens N., Knaapen M.W., Bult H., and Herman A.G. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res 83 (1998) 378-387
20. Burke A., Kolodgie F., Farb A., et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103 (2001) 934-940
21. Galis Z., Sukhova G., Lark M., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
22. Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. Circulation 97 (1998) 2433-2444
23. Guyton J., and Klemp K. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 16 (1996) 4-11
24. Bloch K. Cholesterol: evolution of structure and function. In: Vance D.E., and Vance J.E. (Eds). Biochemistry of Lipids, Lipoproteins and Membranes (1991), Elsevier, Amsterdam 363-381
25. Galis Z., and Khatri J. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good the bad and the ugly. Circ Res 90 (2002) 251-262
26. Libby P., and Lee R. Matrix matters. Circulation 102 (2000) 1874-1884
27. Waterman P., Overhaus M., Heckencamp J., et al. Mechanisms of reduced vascular cell migration after photodynamic therapy. Photochem Photobiol 75 (2001) 46-50
28. Overhaus M., Heckencamp J., Kossodo S., Leszczynski D., and LaMuraglia G.M. Photodynamic therapy generates a matrix barrier to invasive vascular cell migration. Circ Res 86 (2000) 334-340
29. Adili F., Scholz T., Hille M., et al. Photodynamic therapy mediated induction of accelerated re-endothelialisation following injury to the arterial wall: implications for the prevention of postinterventional restenosis. Eur J Vasc Endovasc Surg 24 (2002) 166-175
30. Aikawa M., Rabkin E., Voglic S., et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 83 (1998) 1015-1026
31. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
32. Ambrose J., and Martinez E. A new paradigm for plaque stabilization. Circulation 105 (2002) 2000-2004
33. Farb A., Burke A.P., Kolodgie F.D., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
34. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
35. Jenkins M.P., Buonaccorsi G.A., Raphael M., et al. Clinical study of adjuvant photodynamic therapy to reduce restenosis following femoral angioplasty. Br J Surg 86 (1999) 1258-1263
36. Mansfield R.J., Jenkins M.P., Pai M.L., Bishop C.C., Bown S.G., and McEwan J.R. Long-term safety and efficacy of superficial femoral artery angioplasty with adjuvant photodynamic therapy to prevent restenosis. Br J Surg 89 (2002) 1538-1539
37. Rockson S.G., Kramer P., Razavi M., et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation 102 (2000) 2322-2324
38. Kereiakes D.J., Szyniszewski A.M., Wahr D., et al. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation (2003) 1081310-1081315
39. Jenkins M.P., Buonaccorsi G., MacRobert A., Bishop C.C., Bown S.G., and McEwan J.R. Intra-arterial photodynamic therapy using 5-ALA in a swine model. Eur J Vasc Endovasc Surg 16 (1998) 284-291